Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Medchemexpress LLC Olpasiran sodium | 2225856-03-9 | C490H610F11N164Na42O306P41S7 | 1 MG
Supplier: Medchemexpress LLC HY153492A1MG
Olpasiran sodium is an N-acetyl galactosamine (GalNAc)-conjugated, hepatocyte-targeted siRNA. It directly inhibits LPA messenger RNA translation in hepatocytes and potently reduces Lp(a) concentration. It can be used for the research of cardiovascular disease, such as atherosclerosis.
- N-acetyl galactosamine (GalNAc)-conjugated, hepatocyte-targeted small interfering RNA.
- Potently reduces lipoprotein(a) concentration by directly inhibiting LPA messenger RNA translation.
- Demonstrated efficacy in silencing LPA reporter gene expression in human hepatocellular carcinoma cells.
- Achieves sustained and significant reductions in serum lipoprotein(a) levels in preclinical animal models.
- Potential application in cardiovascular disease research, specifically atherosclerosis.
Product Title
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.
Spot an opportunity for improvement?